Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT)

Tajika, Masahiro; Matsuo, Keitaro; Ito, Hidemi; Chihara, Dai; Bhatia, Vikram; Kondo, Shinya; Tanaka, Tsutomu; Mizuno, Nobumasa; Hara, Kazuo; Hijioka, Susumu; Imaoka, Hiroshi; Matsumoto, Kazuya; Nakamura, Toshiyasu; Yatabe, Yasushi; Yamao, Kenji; Niwa, Yasumasa

doi:10.1007/s00535-013-0844-8

Cited by 13 publications

(12 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An important and new clinico-pathologic observation, yet on a limited number of cases (N = 26) with the possibility of sample bias, was the rather high incidence of metachronous second lymphoid neoplasms in 10% of the patients, which has been documented for gastric MZL, but not for other MZL. 25 We confirm, on the basis of observations of a smaller subgroup (N = 25) of study cases with obtainable FISH results, previous observations that OA-MZL do not bear MALT1 rearrangements. 7 Together with the low frequency and lack of other specific structural chromosomal aberrations in OA-MZL, 2,7,8 this suggests that FISH testing may be of low diagnostic yield.…”

Section: Mutational Landscape Of Oa-mzlsupporting

confidence: 90%

“…The latter finding is supported by our patients' clinical history, showing best treatment responses to local radiotherapy but not to doxycycline. An important and new clinico‐pathologic observation, yet on a limited number of cases (N = 26) with the possibility of sample bias, was the rather high incidence of metachronous second lymphoid neoplasms in 10% of the patients, which has been documented for gastric MZL, but not for other MZL …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B‐cell lymphomas

Vela

Juškevičius

Gerlach

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

The majority of ocular adnexal (OA) lymphomas (OAL) are extranodal marginal zone lymphomas (MZL). First high throughput sequencing (HTS) studies on OA-MZL showed inconsistent results and the distribution of mutations in reactive lymphoid lesions of this anatomic region has not yet been sufficiently addressed. We characterized OAL and lymphoid lesions of the OA by targeted HTS. The study included 34 OA-MZL, 11 chronic conjunctivitis, five mature small cell B-cell lymphomas spreading to the OA, five diseases with increase of IgG4+ plasma cells, three Burkitt lymphomas (BL), three diffuse large B-cell lymphomas (DLBCL), three mantle cell lymphomas, three idiopathic orbital inflammations/orbital pseudo tumors (PT), and three OA lymphoid hyperplasia. All cases were negative for Chlamydia. The mutational number was highest in BL and lowest in PT. The most commonly (and exclusively) mutated gene in OA-MZL was TNFAIP3 (10 of 34 cases). Altogether, 20 out of 34 patients harbored mutually exclusive mutations of either TNFAIP3, BCL10, MYD88, ATM, BRAF, or NFKBIE, or nonexclusive mutations of IRF8, TNFRSF14, KLHL6, and TBL1XR1, all encoding for NK-κB pathway compounds or regulators. Thirteen patients (38%) had, to a great part, mutually exclusive mutations of chromatin modifier-encoding genes: KMT2D, CREBBP, BCL7A, DNMT3A, EP300, or HIST1H1E. Only four patients harbored co-occurring mutations of genes encoding for NK-κB compounds and chromatin modifiers. Finally, PTEN, KMT2D, PRDM1, and HIST1H2BK mutations were observable in reactive lymphoid lesions too, while such instances were devoid of NF-κB compound mutations and/or mutations of acetyltransferase-encoding genes. In conclusion, 80% of OA-MZL display mutations of either NK-κB compounds or chromatin modifiers. Lymphoid lesions of the OA bearing NF-κB compound mutations and/or mutations of acetyltransferase-encoding genes highly likely represent lymphomas.

show abstract

Section: Mutational Landscape Of Oa-mzlsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B‐cell lymphomas

Vela

Juškevičius

Gerlach

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…About 10% of the cases included here developed a second malignancy. This event has already been reported in dogs and people with lymphoma. The causes underlying the development of second malignancies are still unclear, but treatment, above all alkylating agents, has been associated with subsequent malignant neoplasms in human medicine .…”

Section: Discussionsupporting

confidence: 67%

Canine small clear cell/T‐zone lymphoma: clinical presentation and outcome in a retrospective case series

Martini

Marconato

Poggi

et al. 2015

Vet Comparative Oncology

View full text Add to dashboard Cite

Published studies, taken together, suggest the existence of a single canine lymphoma entity, with a small clear cell appearance by cytological evaluation, a histopathological T-zone pattern and an aberrant CD45-negative T-cell phenotype, mostly characterized by long-term survival. We describe clinical presentation and outcome in a retrospective case series of canine small clear cell/T-zone lymphoma. Despite the reported predisposition of Golden retriever, this breed was not represented in our case series. Most dogs presented with stage V disease, whereas only few had clinical signs or peripheral cytopenias. Blood was almost always more infiltrated than bone marrow. Median survival confirmed the favourable prognosis described in literature, but a few dogs died within a short time. Also, a subgroup of dogs developed second malignancies, eventually leading to death. We did not investigate possible prognostic factors because of the wide variety in treatments, and further studies are needed to identify high-risk animals.

show abstract

“…Наблюдение за пациентами с MALT-лимфомой желудка в течение 72 мес показало, что химиотера-пия является независимым фактором риска, вызывая развитие вторых солидных опухолей (ОР 2,91; 95 % ДИ 1,60-4,22) и гемобластозов (ОР 5,54; 95 % ДИ 1,70-9,38) [36].…”

Section: обзорные статьиunclassified

Second primary malignancies in cancer survivors: epidemiology, role of anticancer therapy

Соленова¹

2016

Usp. mol. onkol

View full text Add to dashboard Cite

Успехи в ранней диагностике и лечении злокаче-ственных новообразований (ЗН) привели к более дли-тельной продолжительности жизни онкологических больных, что является индикатором эффективности системы здравоохранения в целом. В России 5-летняя выживаемость онкологических больных выросла с 49,1 % в 1998 г. до 52,9 % в 2015 г. [1,2]. Эти данные совпадают с европейскими, согласно которым средняя 5-летняя выживаемость в 1988-1999 гг. немного превышала 50 % [3]. Данные самого большого кооперативного иссле-дования в Европе (EUROCARE) свидетельствуют об из-менениях в диагностике, лечении ЗН, а также в реа-билита ции онкологических больных, что существенно повлияло на их выживаемость. С 1999-2001 по 2005-2007 гг. значительные успехи были достигнуты в вы-живаемости больных раком предстательной железы (81,7 %), неходжкинской лимфомой (НХЛ) (60,4 %), раком прямой кишки (57,6 %). Показатели сильно ва-

show abstract

Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT)

Abstract: Compared with the general population, patients with gastric MALT lymphoma are at increased risk for second malignancies, including gastric cancer.

Cited by 13 publications

References 41 publications

High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B‐cell lymphomas

High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B‐cell lymphomas

Canine small clear cell/T‐zone lymphoma: clinical presentation and outcome in a retrospective case series

Second primary malignancies in cancer survivors: epidemiology, role of anticancer therapy

Contact Info

Product

Resources

About